Comparison
A4galt Congenital Disorder Of Glycosylation Cn379145 vs 3mc Syndrome 2 C0796279
Clinical comparison between A4galt Congenital Disorder OF Glycosylation CN379145 and 3mc Syndrome 2 for differential diagnosis and treatment planning.
A4galt Congenital Disorder Of Glycosylation Cn379145
A genetic disorder affecting how sugar molecules attach to proteins, impacting multiple body systems. Management focuses on addressing specific symptoms.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
A4galt Congenital Disorder Of Glycosylation Cn379145
0-2
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
A4galt Congenital Disorder Of Glycosylation Cn379145
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
A4galt Congenital Disorder Of Glycosylation Cn379145
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
A4galt Congenital Disorder Of Glycosylation Cn379145
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
A4galt Congenital Disorder Of Glycosylation Cn379145
metabolic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
A4galt Congenital Disorder Of Glycosylation Cn379145
metabolic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
a4galt-congenital-disorder-of-glycosylation-CN379145 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | A4galt Congenital Disorder Of Glycosylation Cn379145 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Primary process | Disordered attachment of sugar molecules to proteins, potentially affecting multiple systems. | Congenital multisystem condition with facial, developmental, and growth manifestations. | High |
| Reported onset | Source onset range is 0–2 years. | Source onset is at birth, coded 0–0. | Moderate |
| Assigned severity | Labeled severe and chronic; this is not an outcome measure. | Labeled moderate and chronic; this is not an outcome measure. | Low |
When to favor each condition
Choose A4galt Congenital Disorder Of Glycosylation Cn379145 when
A glycosylation disorder is the working classification
The left concept is explicitly metabolic and concerns protein glycosylation.
Moderate
Early-childhood rather than strictly birth onset is described
The supplied onset range is 0–2 years, but confirmation is required.
Low
Nonspecific metabolic coding is being considered
E88.9 is supplied, but it does not establish the specific diagnosis.
Low
Choose 3mc Syndrome 2 C0796279 when
Facial, developmental, and growth features predominate
These manifestations are explicitly supplied for 3MC syndrome 2.
Moderate
Features are described as present from birth
The supplied onset is 0–0, consistent with a congenital presentation.
Moderate
A nonspecific congenital-anomaly category is used
Q89.9 is supplied, but it is not diagnostic by itself.
Low
How key tests differ
| Test | A4galt Congenital Disorder Of Glycosylation Cn379145 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Glycosylation evaluation | Potentially relevant because glycosylation is the stated mechanism. | No glycosylation abnormality is established by the source. | An abnormal result is not itself a diagnosis; specialist interpretation is required. |
| Dysmorphology and developmental assessment | Specific facial or growth findings are not supplied. | Facial, developmental, and growth manifestations are described. | Clinical findings support suspicion but do not prove the syndrome. |
| Genetic confirmation | A genetic basis is stated, but the confirmatory test is not specified. | A genetic basis is stated, but the confirmatory test is not specified. | Gene, variant, and inheritance conclusions are not established here. |
Prognosis comparison
A4galt Congenital Disorder Of Glycosylation Cn379145
- Outcome
- Long-term outcome is not established; the source only labels it severe and chronic.
- Factors
- Affected systems and symptom burden may matter, but neither is quantified.
3mc Syndrome 2 C0796279
- Outcome
- Long-term outcome is not established; the source labels it moderate and chronic.
- Factors
- Facial, developmental, and growth manifestations may influence needs.
Time frame: From early life onward; the exact course is not established.
Confirmed diagnosis, involved systems, and supportive-care needs require clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Multisystem involvement | Multiple body systems may be affected; exact complications are not listed. Multiple systems may be affected, with specified developmental and growth features. Specific complication rates and organ risks are not established. |
| Developmental impact | Developmental complications are not specified in the source. Developmental manifestations are explicitly described. Severity and functional outcome require individual clinical assessment. |
| Growth effects | Growth effects are not established from the supplied data. Growth manifestations are part of the supplied description. No growth thresholds or trajectories are provided. |
Patient education highlights
- HighTransmission
Both source entries say the conditions are not communicable; they are not acquired by contact.
- HighDiagnosis
Labels, ICD codes, and abnormal findings do not replace clinician-directed genetic confirmation.
- MediumManagement
Both descriptions emphasize symptom-directed care; no treatment doses or protocols are established here.